You are here: Industry Insights > GSK

News List

GSK to sell stake in Innoviva for $392m pharmaceutical-technology
May 24, 2021
GlaxoSmithKline (GSK) has entered a definitive agreement to sell its entire equity stake in royalty management company Innoviva at $12.25 for each share, taking the deal proceeds to a total of nearly $392m.
Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study worldpharmanews
May 19, 2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that ...
Positive mid-stage results for Medicago and GSK’s plant-derived COVID-19 vaccine pharmatimes
May 18, 2021
Medicago and GlaxoSmithKline’s (GSK) plant-derived COVID-19 vaccine has generated some promising mid-stage trial results, the companies revealed today.
After setback, Sanofi-GSK reports success in COVID-19 vaccine expresspharma
May 18, 2021
The drugmakers said they plan to begin late-stage trials and production in the coming weeks and hope to win regulatory approval for the vaccine before the end of 2021.
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data pharmatimes
May 17, 2021
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced May 13.
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results pharmatimes
May 17, 2021
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups.
EC clears GSK's Benlysta for lupus nephritis pharmatimes
May 07, 2021
The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN).
GSK reports decline in Q1 2021 revenue due to Covid-19 disruption pharmaceutical-technology
April 30, 2021
GlaxoSmithKline (GSK) has reported an 18% year-on-year (YOY) decline in revenue in the first quarter of this year to £7.41bn and down 15% at constant currency due to disruption caused by the global Covid-19 pandemic.
FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
April 26, 2021
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) programmed death receptor-1 (PD-1) blocking antibody Jemperli (dostarlimab-gxly) based on its Biologics License Application (BLA) for endometrial cancer.
Advil to Reduce Plastic in Over 80 Million Bottles by 20% with New Sustainable Plastic Technology americanpharmaceuticalreview
April 21, 2021
GSK Consumer Healthcare, the maker of Advil, announced its commitment to reducing the plastic in over 80 million Advil bottles by 20%, which will result in a reduction of nearly 500,000 pounds of plastic in the environment.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page